ArticleAmerican journal of public health2024
Trends in Medical Encounters Involving Cannabis-Related Disorders Among US Medicare Beneficiaries, 2017-2022.
Abstract read
In one paragraph
Article in American journal of public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Psychological Distress Mediates the Relationship Between Perceived Social Isolation and Medical vs. Recreational Marijuana Use Among Adults in the United States.Psychiatry international · 2026Article
- Prevalence and trends in cannabis use disorder and cannabis poisoning among Medicaid enrollees: a multistate analysis, 2011-2022.Health affairs scholar · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Silvia Perez-VilarSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.ORCID 0000-0003-1272-1502
Sara KazemianSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.
Christina GreeneSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.
Pablo Freyria DuenasSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.
Rose RadinSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.ORCID 0000-0001-6273-274X
Arnstein LindaasSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.
Sandia AkhtarSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.
Michael WerneckeSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.ORCID 0000-0001-9553-3122
Yoganand ChillarigeSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.
Jeffrey A KelmanSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.
David J GrahamSilvia Perez-Vilar, Christina Greene, Rose Radin, and David J. Graham are with the Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Sara Kazemian was with Acumen LLC, Burlingame, CA at the time of the study. Pablo Freyria Duenas, Arnstein Lindaas, Sandia Akhtar, Michael Wernecke, and Yoganand Chillarige are with Acumen LLC, Burlingame, CA. Jeffrey A. Kelman is with the Centers for Medicare & Medicaid Services, Washington, DC.ORCID 0000-0002-7469-4047
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Marijuana AbuseMedicareAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPersons with DisabilitiesUnited StatesYoung Adult
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.